State coverage
Kentucky
Medicaid, for obesity: Does not cover. The conditions and the appeal deadline are in the summary below.
At a glance
- Medicaid, for obesity
- No anti-obesity class on its drug list at all. Wegovy and Zepbound have their own criteria instead.
- Appeal deadline
- 30 calendar days by postmark if the state denied you; 60 days to your plan if an MCO did, then 120 days to a state fair hearing source
- Primary source
- Kentucky Medicaid, Preferred Drug List
- Date read
- September 2026
Kentucky's drug list does not have an anti-obesity section. Not an empty one, not a restricted one — the category is simply not there, and none of these drugs appears anywhere on the list.
That does not mean you cannot get them. Wegovy and Zepbound each have their own criteria, published separately from the list, and both are built around a reason other than weight: heart-attack and stroke risk for Wegovy, sleep apnea for Zepbound.
The sleep apnea route is a hard one. You need a sleep specialist involved, three months on a CPAP or similar machine that did not work, and — the part that catches people out — no diabetes diagnosis and an A1c under 6.5 percent.
One thing is simpler here than in most states. Kentucky law requires a single drug list for every managed care plan, so the answer is the same whichever plan you are in.
What we could verify for Kentucky
Kentucky's drug list has no anti-obesity section. Wegovy, Zepbound, Saxenda, Contrave, Qsymia, Imcivree, phentermine and orlistat are not on it anywhere, and neither are the words "obesity" or "weight loss" — though insulin appears 15 times and glucagon 3, so they are absent from the list rather than from our reading of it. The edition reads "August 2026" on its face.
Kentucky Medicaid, Preferred Drug List, effective August 2026 · source
The GLP-1 class Kentucky does have is a diabetes class. Under the heading "GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS" the list carries Mounjaro pen, Ozempic pen, Trulicity pen and Victoza pen as preferred, with exenatide pen, liraglutide pen, Ozempic tablet, Rybelsus tablet, Soliqua pen and Xultophy pen non-preferred. Neither Wegovy nor Zepbound is in it.
Kentucky Medicaid, Preferred Drug List, effective August 2026 · source
Wegovy is only reachable through heart risk, and Kentucky wants proof you were already on the standard heart drugs first. Initial approval requires "Patient age ≥ 45 years", that it is "Being prescribed for MACE risk reduction (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke)", documented pre-existing cardiovascular disease, and "a claims history showing optimization on specified lipid-lowering therapy (e.g., moderate to high intensity statin, PCSK9)" plus a beta-blocker, a RAS inhibitor or an antiplatelet — or a stated medical reason why none can be used. The patient must also have "a body-mass index (BMI) of 27 kg/m2 or greater". Approval runs 6 months.
Kentucky Medicaid, Prior Authorization Criteria — Wegovy (semaglutide) · source
Zepbound turns partly on a diagnosis you must NOT have. It requires "Prescribed by or in consultation with a neurologist, sleep specialist, or other specialist in the treatment of OSA" and a "≥ 3-month trial and failure, contraindication, or intolerance" of APAP, BiPAP or CPAP therapy, with a BMI of 30 or greater. It then requires that the "Patient does NOT have any of the following: i. A history of diabetes; ii. Current A1c of 6.5% or higher". Age limit 18 and up; approval 6 months.
Kentucky Medicaid, Prior Authorization Criteria — Zepbound (tirzepatide) · source
Your plan does not change the answer, because state law says it cannot. KRS 205.5514 requires that the department "Establish a single preferred drug list to be used by the state pharmacy benefit manager for each managed care organization with whom the department contracts for the delivery of Medicaid services".
Kentucky Revised Statutes 205.5514, Department's duties regarding state pharmacy benefit management, effective March 2020 · source
If the state denied you, the clock is short and measured by postmark. The fee-for-service rule requires that a hearing request "Be postmarked within thirty (30) calendar days from the date of the department's written notice".
907 KAR 1:563, Fee-for-service hearings and appeals · source
If a managed care plan denied you, two longer clocks run in sequence. "An enrollee shall have sixty (60) calendar days from the date of receiving a notice of adverse action from an MCO to file an appeal either orally or in writing with the MCO", and a later state fair hearing request must "Be postmarked or filed within 120 calendar days from the date of the MCO adverse action letter issued at the conclusion of the MCO internal appeal process".
907 KAR 17:010, Managed care organization appeals and state fair hearings · source
Medicaid is only one of the routes. If you have a commercial or employer plan, the rules are different and are on the employer plans page; Medicare has a federal rule of its own, on the Part D page.
If the appeal fails, or you cannot wait
Cash-pay telehealth is the fallback, not the bargain: you pay the whole cost yourself, and a covered prescription is almost always cheaper than any of these. Use this route when coverage has actually been exhausted, or when you need to start while an appeal runs.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
- CoreAge RxAdvertises $99 a month for compounded semaglutide, flat across doses. Read the terms before you sign up: the lander our link opens has shown $149 rather than $99, and a consultation fee can be charged on top and may not be refundable.
- OakFlat price across doses, free shipping with supplies.
- Care Bare RxNames its pharmacies with addresses; sells brand Ozempic as well as compounded.
- Gala HealthAll doses one price, but the advertised rate needs a yearly subscription.
- Synergy RxProviders licensed in your state; publishes no GLP-1 price before the consult.
- Breeze MedsServes all 50 states; publishes a starting price only.
Prices in those notes were read from each company's own site in August 2026 and change often. Check the current number before you buy.
Where this comes from
- Kentucky Medicaid, Preferred Drug List, effective August 2026 — kyportal.medimpact.com/sites/default/files/2023-12/kentucky-medicaid-pdl
- Kentucky Medicaid, Prior Authorization Criteria — Wegovy (semaglutide) — kyportal.medimpact.com/sites/default/files/2026-01/wegovy_pa_criteria_1.
- Kentucky Medicaid, Prior Authorization Criteria — Zepbound (tirzepatide) — kyportal.medimpact.com/sites/default/files/2025-04/zepbound_pa_criteria.
- Kentucky Revised Statutes 205.5514, Department's duties regarding state pharmacy benefit management, effective March 2020 — apps.legislature.ky.gov/law/statutes/statute.aspx?id=49886
- 907 KAR 1:563, Fee-for-service hearings and appeals — apps.legislature.ky.gov/law/kar/titles/907/001/563/
- 907 KAR 17:010, Managed care organization appeals and state fair hearings — apps.legislature.ky.gov/law/kar/titles/907/017/010/
Every state we have verified is in the coverage matrix. Appeal routes and deadlines are on the procedures page.